Sudden cardiac death complicating alcohol septal ablation: A case report and review of literature

Catheterization and Cardiovascular Interventions

Volumn 73, Issue 7, 2009, Pages 956-959

  Antoun, Patrick ^a   El Masry, Hicham ^a   Breall, Jeffrey A ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alcohol septal ablation; Hypertrophic cardiomyopathy; Ventricular fibrillation

Indexed keywords

ALCOHOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ALCOHOL SEPTAL ABLATION; ARTICLE; BRAIN INJURY; CASE REPORT; DEFIBRILLATION; DRUG DOSE TITRATION; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HEART VENTRICLE FIBRILLATION; HUMAN; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; INDUCED HYPOTHERMIA; PERCUTANEOUS CORONARY INTERVENTION; RESUSCITATION; SUDDEN DEATH;

CARDIOMYOPATHY, HYPERTROPHIC; CARDIOPULMONARY RESUSCITATION; CATHETER ABLATION; CORONARY ANGIOGRAPHY; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS; ETHANOL; FEMALE; HUMANS; HYPOTHERMIA, INDUCED; MIDDLE AGED; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 68249157953     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.21849     Document Type: Article

References (19)

1. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:211-214.
2. Tekieli L, Pieniazek P, Podolec P, et al. Percutaneous transluminal septal myocardial ablation: Early results and long-term follow-up. Przeglad Lekarski 2006;63:628-632.
3. Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Clin Res Cardiol 2007;96: 856-863.
4. Olivotto I, Ommen SR, Maron MS, Cecchi F, Maron BJ. Surgical myectomy versus alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Will there ever be a randomized trial? J Am Coll Cardiol 2007;50:831-834.
5. Knight CJ. Alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Heart 2006;92:1339-1344.
6. Alam M, Dokainish H, Lakkis N. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A systematic review of published studies. J Interv Cardiol 2006;19:319-327.
7. Knight C, Kurbaan AS, Seggewiss H, Henein M, Gunning M, Harrington D, Fassbender D, Gleichmann U, Sigwart U. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: Outcome in the first series of patients. Circulation 1997;95: 2075-2081.
8. Holmes DR Jr, Valeti US, Nishimura RA. Alcohol septal ablation for hypertrophic cardiomyopathy: Indications and technique. Cathet Cardiovasc Interv 2005;66:375-389.
9. Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH III. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up. J Am Coll Cardiol 2000;36:852-855.
10. Simon RDB, Crawford FA III, Spencer WH III, Gold MR. Sustained ventricular tachycardia following alcohol septal ablation for hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2005;28:1354-1356.
11. McGregor JB, Rahman A, Rosanio S, Ware D, Birnbaum Y, Saeed M. Monomorphic ventricular tachycardia: A late complication of percutaneous alcohol septal ablation for hypertrophic cardiomyopathy. Am J Med Sci 2004;328:185-188.
12. Hori Y, Ueda M, Nakayama T, et al. Occurrence of de novo sustained monomorphic ventricular tachycardia induced after percutaneous transluminal alcohol septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Int J Cardiol 2007; 119:403-407.
13. Boltwood CM Jr, Chien W, Ports T. Ventricular tachycardia complicating alcohol septal ablation. N Engl J Med 2004;351: 1914-1915.
14. Kuhn H, Gietzen FH, Leuner C, et al. Transcoronary ablation of septal hypertrophy (TASH): A new treatment option for hypertrophic obstructive cardiomyopathy. Zeitschrift fur Kardiologie 2000;89 (Suppl 4):IV41-IV54.
15. Lawrenz T, Obergassel L, Lieder F, Leuner C, Strunk-Mueller C, Meyer Zu Vilsendorf D, Beer G, Kuhn H. Transcoronary ablation of septal hypertrophy does not alter ICD intervention rates in high risk patients with hypertrophic obstructive cardiomyopathy. Pacing Clin Electrophysiol 2005;28:295-300.
16. van Dockum WG, ten Cate FJ, ten Berg JM, Beek AM, Twisk JWR, Vos J, Hofman MBM, Visser CA, van Rossum AC. Myocardial infarction after percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Evaluation by contrast-enhanced magnetic resonance imaging. J Am Coll Cardiol 2004;43:27-34.
17. van der Lee C, Scholzel B, ten Berg JM, Geleijnse ML, Idzerda HH, van Domburg RT, Vletter WB, Serruys PW, ten Cate FJ. Usefulness of clinical, echocardiographic, and procedural characteristics to predict outcome after percutaneous transluminal septal myocardial ablation. Am J Cardiol 2008; 101:1315-1320.
18. Amano Y, Takayama M, Kumita S, Kumazaki T. MR imaging evaluation of regional, remote, and global effects of percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy. J Comput Assist Tomogr 2007;31: 600-604.
19. Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation 2007;116:196-206; discussion 206.